Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 3, 2016, Pages 699-706

  Fu, Alex Z ^a,b   Graves, Kristi D ^a,b   Jensen, Roxanne E ^a,b   Marshall, John L ^b   Formoso, Margaret ^b   Potosky, Arnold L ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Metastatic colorectal cancer; Patient preference; Standard gamble; Tradeoff; Treatment decision making

Indexed keywords

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BIOLOGICAL THERAPY; BLOOD CLOT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; EMPLOYMENT STATUS; FATIGUE; FEMALE; HAIR LOSS; HEALTH INSURANCE; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERTENSION; INCOME; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NAUSEA AND VOMITING; NEUROPATHY; PAIN; PATIENT DECISION MAKING; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SYMPTOM; COGNITION; COLORECTAL NEOPLASMS; DECISION MAKING; METASTASIS; MIDDLE AGED; PATHOLOGY; PATIENT PREFERENCE; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ANTINEOPLASTIC AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT PREFERENCE; SURVEYS AND QUESTIONNAIRES; VOLITION;

EID: 84957946099     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2073-4     Document Type: Article

References (42)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AE (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, Berlin
2. Arora NK, Hesse BW, Rimer BK, Viswanath K, Clayman ML, Croyle RT (2008) Frustrated and confused: the American public rates its cancer-related information-seeking experiences. J Gen Intern Med 23:223–228
3. Audrey S, Abel J, Blazeby JM, Falk S, Campbell R (2008) What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study. BMJ 337:a752
4. Back A, Arnold RM, Baile WF, Tulsky JA, Fryer-Edwards K (2010) Improving oncologists’ communication skills. http://depts.washington.edu/oncotalk. Accessed 20 Dec 2013
5. Choueiri TK, Mayer EL, Je Y et al (2011) Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632–638
6. CMS (2014) Clinical quality measures. http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/ClinicalQualityMeasures.html
7. Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW (1998) The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 18:376–380
8. Craig BM, Reeve BB, Cella D, Hays RD, Pickard AS, Revicki DA (2014) Demographic differences in health preferences in the United States. Med Care 52:307–313
9. Epner DE, Baile WF (2014) Difficult conversations: teaching medical oncology trainees communication skills one hour at a time. Acad Med 89:578–584
10. Fischer G, Kamlet MS, Fienberg S, Schkade D (1986) Risk preference for gains and losses in multiple objective decision making. Manag Sci 31:1065–1086
11. Fu AZ, Kattan MW (2006) Racial and ethnic differences in preference-based health status measure. Curr Med Res Opin 22:2439–2448
12. Galfrascoli E, Piva S, Cinquini M et al (2011) Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 43:286–294
13. Ganz P (2015) Quality of cancer care, plenary address. Washington, DC, world congress of psycho-oncology, from national to global: implementing the standard of psychosocial care in oncology
14. Gattellari M, Butow PN, Tattersall MH (2001) Sharing decisions in cancer care. Soc Sci Med 52:1865–1878
15. Goelz T, Wuensch A, Stubenrauch S et al (2011) Specific training program improves oncologists’ palliative care communication skills in a randomized controlled trial. J Clin Oncol 29:3402–3407
16. Grothey A, Van CE, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312
17. Hahn EA, Cella D, Dobrez DG et al (2007) The impact of literacy on health-related quality of life measurement and outcomes in cancer outpatients. Qual Life Res 16:495–507
18. Harris KA (1998) The informational needs of patients with cancer and their families. Cancer Pract 6:39–46
19. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342
20. Institute of Medicine (2013) Delivering high-quality cancer care: charting a new course for a system in crisis. National Academies Press, Washington, DC
21. Kaldjian LC, Curtis AE, Shinkunas LA, Cannon KT (2008) Goals of care toward the end of life: a structured literature review. Am J Hosp Palliat Care 25:501–511
22. Kattan MW (2003) Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology (Williston Park) 17:1687–1693
23. Kattan MW, Cowen ME, Miles BJ (1997) A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12:299–305
24. Laryionava K, Heussner P, Hiddemann W, Winkler EC (2015) Framework for timing of the discussion about forgoing cancer-specific treatment based on a qualitative study with oncologists. Support Care Cancer 23:715–721
25. Leighl NB, Butow PN, Tattersall MH (2004) Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear. J Clin Oncol 22:1759–1762
26. Leighl NB, Shepherd HL, Butow PN et al (2011) Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol 29:2077–2084
27. Ness RM, Holmes A, Klein R, Greene J, Dittus R (1998) Outcome states of colorectal cancer: identification and description using patient focus groups. Am J Gastroenterol 93:1491–1497
28. Ness RM, Holmes AM, Klein R, Dittus R (1999) Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 94:1650–1657
29. O’Connor AM, Rostom A, Fiset V et al (1999) Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 319:731–734
30. Prigerson HG, Bao Y, Shah MA et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1:778–784
31. Ramlau R, Gorbunova V, Ciuleanu TE et al (2012) Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 30:3640–3647
32. Ross PL, Littenberg B, Fearn P, Scardino PT, Karakiewicz PI, Kattan MW (2003) Paper standard gamble: a paper-based measure of standard gamble utility for current health. Int J Technol Assess Health Care 19:135–147
33. Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261
34. Semenza GL (2008) A new weapon for attacking tumor blood vessels. N Engl J Med 358:2066–2067
35. Street RL Jr, Voigt B (1997) Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Making 17:298–306
36. Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G (2006) Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns 63:104–109
37. Sullivan PW, Lawrence WF, Ghushchyan V (2005) A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43:736–749
38. Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40:593–603
39. Walling A, Lorenz KA, Dy SM et al (2008) Evidence-based recommendations for information and care planning in cancer care. J Clin Oncol 26:3896–3902
40. Weeks JC, Catalano PJ, Cronin A et al (2012) Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616–1625
41. Wright AA, Zhang B, Ray A et al (2008) Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300:1665–1673
42. Zafar SY, Malin JL, Grambow SC et al (2013) Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer 119:854–862